The Geriatric Medicine Market size was valued at USD 169.9 billion in 2024 and is expected to reach USD 304.7 billion by 2032, growing at a CAGR of 7.58% over the forecast period 2025-2032.
To Get more information on Geriatric Medicine Market - Request Free Sample Report
Rising global aging population and growing frequency of chronic disorders among seniors are driving a strong rise in the geriatric medicine market. The United Nations estimates that the global population aged 65 and above, up from 761 million in 2021, will reach 1.6 billion by 2025, underscoring the increasing need for tailored healthcare solutions for elderly persons. Government agencies are responding with enlarged insurance schemes and policy incentives.
For instance, India's proposed expansion of Ayushman Bharat to cover all individuals over 70 and the U.S. Inflation Reduction Act's Medicare Part D reforms, which cap out-of-pocket prescription drug costs for seniors.
Driven by advanced healthcare infrastructure, high chronic disease prevalence, and favourable reimbursement policies, the U.S. geriatric medicine market held 78% of the North American market share and valued USD 50.30 billion in 2023 and is expected to reach USD 89.43 billion by 2032 with a CAGR of 7.46% over the forecast period. 1 in 6 Americans is above 65 years old. These developments are influencing present geriatric medicine market trends and driving the notable increase in the geriatric medicine market.
The growing elderly population and rising incidence of chronic diseases, including diabetes, cardiovascular diseases, and neurological ailments, are driving fast expansion in the global geriatric medicine market. The World Health Organization emphasizes the vital requirement of efficient medicine for older adults and thorough chronic disease care in elderly populations, since over 50% of all fatalities in persons aged 65 and above are linked to chronic diseases. Government programs improving access to geriatric healthcare solutions include increased insurance coverage and the building of specialized geriatric healthcare solutions.
Market Dynamics:
Drivers:
Rising Global Geriatric Population and Prevalence of Chronic Diseases Drive Demand for Specialized Medicines and Healthcare Solutions
The global elderly population is expanding at a historic pace, with those aged 65 and above representing the fastest-growing demographic segment globally. The rising frequency of chronic ailments include neurological problems, diabetes, arthritis, and cardiovascular diseases, which are disproportionately common among older adults. Growing rates of hypertension and other age-related diseases drive the global market. The demand for long-term and specialized pharmacological treatment increases as populations in nations including China, India, and the U.S. age rapidly. These changes drive pharmaceutical companies to create customized treatments and creative drug delivery systems, thereby assuring that the particular medical needs of the elderly are satisfied with more effectiveness and safety. The combination of demographic changes and the weight of chronic illness is fundamentally changing the terrain of geriatric healthcare. Therefore, this sector is becoming a focus point for industry investment and global health policy.
Restraints:
Significant Obstacles to Innovation and Market Entry Created by High Drug Development Costs and Strict Regulatory Requirements
The development of geriatric medicines is fraught with high costs and complex regulatory hurdles, which significantly restrain market growth. Especially considering the higher risk of adverse effects and polypharmacy in senior patients, bringing a new drug to market calls for thorough research, rigorous clinical studies, and strict adherence to regulatory criteria. Often making it difficult for smaller pharmaceutical companies to compete, regulatory authorities want thorough safety and efficacy data, which extends research timelines and increases expenses.
These obstacles may hinder the introduction of new treatments and slow down the speed of innovation. Further complicating the clearance procedure is the necessity of designing research considering several co-morbidities and different physiological reactions in older people. These difficulties not only restrict the number of new competitors but also discourage research and development investment, therefore influencing the availability of sophisticated treatment choices for the aging population.
By Therapeutic Category
Antihypertensive therapeutics accounted for 21% of the geriatric medicine market share in 2024. The great frequency of hypertension in elderly people is reflected in the dominance of antihypertensive pharmaceuticals in the elderly care pharmaceuticals market. With over two-thirds of Americans aged 60+ diagnosed with hypertension, cardiovascular drugs for the elderly is an essential geriatric care tool. Frequent government health screenings and the incorporation of combination medicines to solve polypharmacy in geriatric patients fuel the expansion of the geriatric medicine market. Innovations and recent legislative changes are influencing the trends in the geriatric medicine market.
For instance, in May 2023, the U.S. FDA authorized a new triple-combining antihypertensive therapy meant to lower tablet load and boost senior adherence.
The Inflation Reduction Act of 2022, implemented in 2024, eliminated the 5% coinsurance requirement for Medicare Part D enrollees in the catastrophic phase, capping out-of-pocket drug costs and making Prescription Drugs for Seniors more affordable.
According to the International Diabetes Federation estimates that over 25% of persons aged 65+ globally have diabetes, anti- diabetic treatments are showing interesting Geriatric Medicine Market Growth. Adoption in this market is being driven by the introduction of improved GLP-1 receptor agonists and SGLT2 inhibitors, which offer renal and cardiovascular advantages. Reflecting the focus of the market on customized geriatric healthcare solutions, the European Medicines Agency approved a once-weekly injectable antidiabetic medication with proven cardiovascular advantages for seniors in June 2024.
The 2024 budget for India suggested expanding Ayushman Bharat to cover all seniors over 70, boost insurance coverage, and provide medication for older adults’ access.
By Condition
Cardiovascular illnesses led with 33% of the geriatric medicine market share in 2024 as cardiovascular diseases remain the leading cause of morbidity and mortality among the elderly. The World Health Organization drives demand for cardiovascular medications for the elderly since over half of their deaths are attributed to heart-related diseases. Expanding coverage for cardiac rehabilitation in 2024, the U.S. Centers for Medicare & Medicaid Services supports the geriatric medicine market expansion and increases medicare beneficiary involvement.
For instance, the European Commission's "Active Aging" initiative allocated €500 million in 2023 for age-friendly healthcare infrastructure, supporting cardiovascular and diabetes management for seniors.
Diabetes and metabolic disorders experienced exponential growth. With the CDC estimating 27% of Americans aged 65+ have diabetes as of 2024, diabetes and metabolic diseases are also expanding. Government-backed digital health projects, such as the U.K. NHS's statewide digital diabetes care program for seniors, which has improved glycemic control and lowered hospital admissions, drive the segment's exponential growth.
By Distribution Channel
With a 46% share in 2024, retail pharmacies dominated the market and remain the main source of prescription pharmaceuticals for seniors. Reflecting their important position in medication adherence and chronic disease management, the U.S. Department of Health and Human Services notes that 85% of persons aged 65+ fill prescriptions at retail pharmacies. The expansion of pharmacy-driven health services, such as medication therapy management and immunizations, is further strengthening this segment.
For instance, the establishment of Jan Aushadhi Kendras and e-Pharmacy projects by the Indian government in 2024 has enhanced pharmaceutical availability for urban and rural elderly, thereby supporting geriatric medicine market trends.
Online pharmacies segment is growing significantly driven by the acceptance of telemedicine and digital health systems, further increasing their popularity in the market. While India's "e-Pharmacy" project provided digital access to vital medications for over 10 million seniors, the U.K. NHS reported in 2024 a 35% increase in online pharmacy registrations among seniors. The 2024 recommendations for online prescription drug dispensing by the European Medicines Agency are projected to improve patient safety and assist the geriatric medicine market growth.
Regional Analysis:
With a 38% market share in 2024, North America still dominates the global geriatric medicine market. The U.S. held 78% of the North American region's share.
Several factors, such as a strong government backing, significant healthcare expenditure, and an advanced and developed healthcare infrastructure are responsible for region’s growth in the market. Among the aged in the area, chronic diseases, such as diabetes, arthritis, and cardiovascular diseases are rather common, which increases the demand for specific treatments and thorough chronic disease management in elderly.
Further driving market expansion are favourable reimbursement policies of the U.S. government, regular FDA drug approvals, and tax incentives for geriatric medicine companies. Furthermore, technology innovations including digital health records, remote patient monitoring, and telemedicine, are improving the effectiveness of geriatric healthcare solutions. Canada, while smaller in market size, also benefits from universal healthcare and targeted elderly care programs, contributing to the region’s overall dominance.
Europe holds the second-largest share in the geriatric medicine market, with significant variations across countries. With an estimated 30% of the overall population by 2025, the elderly population of the region aged 65 and above is significant and expanding. Since older persons are the main users of prescription drugs for seniors and often need several medications-over 10% of Europe's elderly population receives 10 or more drugs routinely, this demographic change is a main driver of market demand. Public insurance programs and government projects abound, promoting medication for older adults and encouraging pharmaceutical innovation. Leading nations in the acceptance of robot-assisted surgical procedures, advanced treatments, and senior-specific customized therapy are Germany and the U.K. By providing rules that guarantee the special needs of elderly patients are met in drug research and certification, the European Medicines Agency (EMA) plays an important role.
Asia Pacific is the fastest-growing region in the market with a CAGR of 8.11% over the forecast period. This growth is driven by the older population, especially in China, Japan, and India fuels this fast growth. China leads the region with its large and rising aging population, government changes meant to enhance elder care, and higher senior insurance coverage. Driven by urbanization, increasing healthcare expenditures, and state support for elder care, India is also becoming a major market.
For instance, India’s 2024 budget proposals for senior healthcare coverage are expected to significantly boost the aging population healthcare market in Asia Pacific.
The region benefits from improving the infrastructure for healthcare, including both generic and patented medications, and raising knowledge of preventative care and good living. Governments are aggressively funding healthcare institutions and starting projects to make geriatric medications more reasonably priced and easily available. The great frequency of chronic diseases, such as Parkinson's, Alzheimer's, diabetes, and cardiovascular diseases among the elderly drives an even greater need for geriatric healthcare solutions. Growing disposable incomes and the rise of medical sectors in underdeveloped nations also help to explain the growth of the Asia Pacific region.
The LAMEA region, while smaller in overall market share, is experiencing steady growth in the market. Investing in healthcare reforms, increasing insurance coverage, and starting public health projects targeted at the elderly are Brazil, Mexico, and Middle Eastern nations. Under its "Healthy Aging" campaign, the Brazilian government has raised senior vaccination rates and conducted chronic disease tests, therefore encouraging market growth. The area presents special difficulties, including differences in infrastructure and healthcare access, but constant investments and international partnerships are progressively improving the landscape.
Get Customized Report as per Your Business Requirement - Enquiry Now
The key geriatric medicine companies are F. Hoffmann-La Roche Ltd., Takeda Pharmaceutical Company Ltd., Eli Lilly & Company, AbbiVie, Inc, Amgen, Inc, Pfizer, Inc, Novartis AG, Abbott Laboratories Inc., Bristol-Myers Squibb Company, UCB, Inc., Merck and Co., Inc, Sanofi, GSK plc, Johnson and Johnson Services, Inc., AstraZeneca PLC, and others.
Recent Developments:
A significant development in geriatric healthcare solutions came when the U.S. FDA approved Pfizer's ABRYSVO, a bivalent RSV vaccination for individuals aged 60+, in May 2023.
FDA approved Pfizer Inc.'s bivalent RSV vaccine, ABRYSVO, in May 2023 to help adults 60 years of age and above avoid lower respiratory tract sickness brought on by RSV.
Geriatric Medicine Market Report Scope:
| Report Attributes | Details |
|---|---|
| Market Size in 2024 | USD 169.9 Billion |
| Market Size by 2032 | USD 307.4 Billion |
| CAGR | CAGR of 7.58% From 2025 to 2032 |
| Base Year | 2024 |
| Forecast Period | 2025-2032 |
| Historical Data | 2021-2023 |
| Report Scope & Coverage | Market Size, Segments Analysis, Competitive Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook |
| Key Segments | • By Condition (Cardiovascular Diseases, Cancer, Arthritis & Bone Health, Respiratory Diseases, Neurological Disorders, Diabetes and Metabolic Disorders, and Others) • By Therapeutics (Analgesics, Antihypertensive, Proton Pump Inhibitors, Statins, Antidiabetic, Anticoagulant, Antipsychotic, and Others) • By Distribution Channel (Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy) |
| Regional Analysis/Coverage | North America (US, Canada, Mexico), Europe (Germany, France, UK, Italy, Spain, Poland, Turkey, Rest of Europe), Asia Pacific (China, India, Japan, South Korea, Singapore, Australia, Rest of Asia Pacific), Middle East & Africa (UAE, Saudi Arabia, Qatar, South Africa, Rest of Middle East & Africa), Latin America (Brazil, Argentina, Rest of Latin America) |
| Company Profiles | F. Hoffmann-La Roche Ltd., Takeda Pharmaceutical Company Ltd., Eli Lilly & Company, AbbiVie, Inc, Amgen, Inc, Pfizer, Inc, Novartis AG, Abbott Laboratories Inc., Bristol-Myers Squibb Company, UCB, Inc., Merck and Co., Inc, Sanofi, GSK plc, Johnson and Johnson Services, Inc., AstraZeneca PLC, and others. |
Ans. The projected market size for the Geriatric Medicine Market is USD 304.7 billion by 2032.
Ans: The North American region dominated the Geriatric Medicine Market in 2023.
Ans. The CAGR of the Geriatric Medicine Market is 7.58% during the forecast period of 2025-2032.
Ans:
Ans: The Retail Pharmacies segment dominated the Geriatric Medicine Market.
1. Introduction
1.1 Market Definition
1.2 Scope (Inclusion and Exclusions)
1.3 Research Assumptions
2. Executive Summary
2.1 Market Overview
2.2 Regional Synopsis
2.3 Competitive Summary
3. Research Methodology
3.1 Top-Down Approach
3.2 Bottom-up Approach
3.3. Data Validation
3.4 Primary Interviews
4. Market Dynamics Impact Analysis
4.1 Market Driving Factors Analysis
4.1.1 Drivers
4.1.2 Restraints
4.1.3 Opportunities
4.1.4 Challenges
4.2 PESTLE Analysis
4.3 Porter’s Five Forces Model
5. Statistical Insights and Trends Reporting
5.1 Prescription Trends in Geriatric Medicine (2023), by Region
5.2 Healthcare Spending on Geriatric Care, by Source (2023)
5.3 Infrastructure and Service Trends in Geriatric Medicine
5.4 Regulatory and Policy Shifts Impacting Geriatric Care
6. Competitive Landscape
6.1 List of Major Companies, By Region
6.2 Market Share Analysis, By Region
6.3 Product Benchmarking
6.3.1 Product specifications and features
6.3.2 Pricing
6.4 Strategic Initiatives
6.4.1 Marketing and promotional activities
6.4.2 Distribution and Supply Chain Strategies
6.4.3 Expansion plans and new Product launches
6.4.4 Strategic partnerships and collaborations
6.5 Technological Advancements
6.6 Market Positioning and Branding
7. Geriatric Medicine Market Segmentation By Condition
7.1 Chapter Overview
7.2 Cardiovascular Diseases
7.2.1 Cardiovascular Diseases Market Trends Analysis (2021-2032)
7.2.2 Cardiovascular Diseases Market Size Estimates and Forecasts to 2032 (USD Billion)
7.3 Cancer
7.3.1 Cancer Market Trends Analysis (2021-2032)
7.3.2 Cancer Market Size Estimates and Forecasts to 2032 (USD Billion)
7.4 Arthritis & Bone Health
7.4.1 Arthritis & Bone Health Market Trends Analysis (2021-2032)
7.4.2 Arthritis & Bone Health Market Size Estimates and Forecasts to 2032 (USD Billion)
7.5 Respiratory Diseases
7.5.1 Respiratory Diseases Market Trends Analysis (2021-2032)
7.5.2 Respiratory Diseases Market Size Estimates and Forecasts to 2032 (USD Billion)
7.6 Neurological Disorders
7.6.1 Neurological Disorders Market Trends Analysis (2021-2032)
7.6.2 Neurological Disorders Market Size Estimates and Forecasts to 2032 (USD Billion)
7.7 Diabetes and Metabolic Disorders
7.7.1 Diabetes and Metabolic Disorders Market Trends Analysis (2021-2032)
7.7.2 Diabetes and Metabolic Disorders Market Size Estimates and Forecasts to 2032 (USD Billion)
7.8 Others
7.8.1 Others Market Trends Analysis (2021-2032)
7.8.2 Others Market Size Estimates and Forecasts to 2032 (USD Billion)
8. Geriatric Medicine Market Segmentation By Therapeutics
8.1 Chapter Overview
8.2 Analgesics
8.2.1 Analgesics Market Trend Analysis (2021-2032)
8.2.2 Analgesics Market Size Estimates and Forecasts to 2032 (USD Billion)
8.3 Antihypertensive
8.3.1 Antihypertensive Market Trends Analysis (2021-2032)
8.3.2 Antihypertensive Market Size Estimates and Forecasts to 2032 (USD Billion)
8.4 Proton Pump Inhibitors
8.4.1 Proton Pump Inhibitors Market Trends Analysis (2021-2032)
8.4.2 Proton Pump Inhibitors Market Size Estimates and Forecasts to 2032 (USD Billion)
8.5 Statins
8.5.1 Statins Market Trends Analysis (2021-2032)
8.5.2 Statins Market Size Estimates and Forecasts to 2032 (USD Billion)
8.6 Antidiabetic
8.6.1 Antidiabetic Market Trends Analysis (2021-2032)
8.6.2 Antidiabetic Market Size Estimates and Forecasts to 2032 (USD Billion)
8.7 Anticoagulant
8.7.1 Anticoagulant Market Trends Analysis (2021-2032)
8.7.2 Anticoagulant Market Size Estimates and Forecasts to 2032 (USD Billion)
8.8 Antipsychotic
8.8.1 Antipsychotic Market Trends Analysis (2021-2032)
8.8.2 Antipsychotic Market Size Estimates and Forecasts to 2032 (USD Billion)
8.9 Others
8.9.1 Others Market Trends Analysis (2021-2032)
8.9.2 Others Market Size Estimates and Forecasts to 2032 (USD Billion)
9. Geriatric Medicine Market Segmentation By Distribution Channel
9.1 Chapter Overview
9.2 Hospital Pharmacies
9.2.1 Hospital Pharmacies Market Trends Analysis (2021-2032)
9.2.2 Hospital Pharmacies Market Size Estimates and Forecasts to 2032 (USD Billion)
9.3 Retail Pharmacies
9.3.1 Retail Pharmacies Market Trends Analysis (2021-2032)
9.3.2 Retail Pharmacies Market Size Estimates and Forecasts to 2032 (USD Billion)
9.4 Online Pharmacies
9.4.1 Online Pharmacies Market Trends Analysis (2021-2032)
9.4.2 Online Pharmacies Market Size Estimates and Forecasts to 2032 (USD Billion)
10. Regional Analysis
10.1 Chapter Overview
10.2 North America
10.2.1 Trends Analysis
10.2.2 North America Geriatric Medicine Market Estimates and Forecasts, by Country (2021-2032) (USD Billion)
10.2.3 North America Geriatric Medicine Market Estimates and Forecasts, By Condition (2021-2032) (USD Billion)
10.2.4 North America Geriatric Medicine Market Estimates and Forecasts, By Therapeutics (2021-2032) (USD Billion)
10.2.5 North America Geriatric Medicine Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.2.6 USA
10.2.6.1 USA Geriatric Medicine Market Estimates and Forecasts, By Condition (2021-2032) (USD Billion)
10.2.6.2 USA Geriatric Medicine Market Estimates and Forecasts, By Therapeutics (2021-2032) (USD Billion)
10.2.6.3 USA Geriatric Medicine Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.2.7 Canada
10.2.7.1 Canada Geriatric Medicine Market Estimates and Forecasts, By Condition (2021-2032) (USD Billion)
10.2.7.2 Canada Geriatric Medicine Market Estimates and Forecasts, By Therapeutics (2021-2032) (USD Billion)
10.2.7.3 Canada Geriatric Medicine Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.2.8 Mexico
10.2.8.1 Mexico Geriatric Medicine Market Estimates and Forecasts, By Condition (2021-2032) (USD Billion)
10.2.8.2 Mexico Geriatric Medicine Market Estimates and Forecasts, By Therapeutics (2021-2032) (USD Billion)
10.2.8.3 Mexico Geriatric Medicine Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.3 Europe
10.3.1 Trends Analysis
10.3.2 Europe Geriatric Medicine Market Estimates and Forecasts, by Country (2021-2032) (USD Billion)
10.3.3 Europe Geriatric Medicine Market Estimates and Forecasts, By Condition (2021-2032) (USD Billion)
10.3.4 Europe Geriatric Medicine Market Estimates and Forecasts, By Therapeutics (2021-2032) (USD Billion)
10.3.5 Europe Geriatric Medicine Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.3.6 Germany
10.3.6.1 Germany Geriatric Medicine Market Estimates and Forecasts, By Condition (2021-2032) (USD Billion)
10.3.6.2 Germany Geriatric Medicine Market Estimates and Forecasts, By Therapeutics (2021-2032) (USD Billion)
10.3.6.3 Germany Geriatric Medicine Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.3.7 France
10.3.7.1 France Geriatric Medicine Market Estimates and Forecasts, By Condition (2021-2032) (USD Billion)
10.3.7.2 France Geriatric Medicine Market Estimates and Forecasts, By Therapeutics (2021-2032) (USD Billion)
10.3.7.3 France Geriatric Medicine Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.3.8 UK
10.3.8.1 UK Geriatric Medicine Market Estimates and Forecasts, By Condition (2021-2032) (USD Billion)
10.3.8.2 UK Geriatric Medicine Market Estimates and Forecasts, By Therapeutics (2021-2032) (USD Billion)
10.3.8.3 UK Geriatric Medicine Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.3.9 Italy
10.3.9.1 Italy Geriatric Medicine Market Estimates and Forecasts, By Condition (2021-2032) (USD Billion)
10.3.9.2 Italy Geriatric Medicine Market Estimates and Forecasts, By Therapeutics (2021-2032) (USD Billion)
10.3.9.3 Italy Geriatric Medicine Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.3.10 Spain
10.3.10.1 Spain Geriatric Medicine Market Estimates and Forecasts, By Condition (2021-2032) (USD Billion)
10.3.10.2 Spain Geriatric Medicine Market Estimates and Forecasts, By Therapeutics (2021-2032) (USD Billion)
10.3.10.3 Spain Geriatric Medicine Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.3.11 Poland
10.3.11.1 Poland Geriatric Medicine Market Estimates and Forecasts, By Condition (2021-2032) (USD Billion)
10.3.11.2 Poland Geriatric Medicine Market Estimates and Forecasts, By Therapeutics (2021-2032) (USD Billion)
10.3.11.3 Poland Geriatric Medicine Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.3.12 Turkey
10.3.12.1 Turkey Geriatric Medicine Market Estimates and Forecasts, By Condition (2021-2032) (USD Billion)
10.3.12.2 Turkey Geriatric Medicine Market Estimates and Forecasts, By Therapeutics (2021-2032) (USD Billion)
10.3.12.3 Turkey Geriatric Medicine Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.3.13 Rest of Europe
10.3.13.1 Rest of Europe Geriatric Medicine Market Estimates and Forecasts, By Condition (2021-2032) (USD Billion)
10.3.13.2 Rest of Europe Geriatric Medicine Market Estimates and Forecasts, By Therapeutics (2021-2032) (USD Billion)
10.3.13.3 Rest of Europe Geriatric Medicine Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.4 Asia Pacific
10.4.1 Trends Analysis
10.4.2 Asia Pacific Geriatric Medicine Market Estimates and Forecasts, by Country (2021-2032) (USD Billion)
10.4.3 Asia Pacific Geriatric Medicine Market Estimates and Forecasts, By Condition (2021-2032) (USD Billion)
10.4.4 Asia Pacific Geriatric Medicine Market Estimates and Forecasts, By Therapeutics (2021-2032) (USD Billion)
10.4.5 Asia Pacific Geriatric Medicine Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.4.6 China
10.4.6.1 China Geriatric Medicine Market Estimates and Forecasts, By Condition (2021-2032) (USD Billion)
10.4.6.2 China Geriatric Medicine Market Estimates and Forecasts, By Therapeutics (2021-2032) (USD Billion)
10.4.6.3 China Geriatric Medicine Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.4.7 India
10.4.7.1 India Geriatric Medicine Market Estimates and Forecasts, By Condition (2021-2032) (USD Billion)
10.4.7.2 India Geriatric Medicine Market Estimates and Forecasts, By Therapeutics (2021-2032) (USD Billion)
10.4.7.3 India Geriatric Medicine Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.4.8 Japan
10.4.8.1 Japan Geriatric Medicine Market Estimates and Forecasts, By Condition (2021-2032) (USD Billion)
10.4.8.2 Japan Geriatric Medicine Market Estimates and Forecasts, By Therapeutics (2021-2032) (USD Billion)
10.4.8.3 Japan Geriatric Medicine Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.4.9 South Korea
10.4.9.1 South Korea Geriatric Medicine Market Estimates and Forecasts, By Condition (2021-2032) (USD Billion)
10.4.9.2 South Korea Geriatric Medicine Market Estimates and Forecasts, By Therapeutics (2021-2032) (USD Billion)
10.4.9.3 South Korea Geriatric Medicine Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.4.10 Singapore
10.4.10.1 Singapore Geriatric Medicine Market Estimates and Forecasts, By Condition (2021-2032) (USD Billion)
10.4.10.2 Singapore Geriatric Medicine Market Estimates and Forecasts, By Therapeutics (2021-2032) (USD Billion)
10.4.10.3 Singapore Geriatric Medicine Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.4.11 Australia
10.4.11.1 Australia Geriatric Medicine Market Estimates and Forecasts, By Condition (2021-2032) (USD Billion)
10.4.11.2 Australia Geriatric Medicine Market Estimates and Forecasts, By Therapeutics (2021-2032) (USD Billion)
10.4.11.3 Australia Geriatric Medicine Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.4.12 Rest of Asia Pacific
10.4.12.1 Rest of Asia Pacific Geriatric Medicine Market Estimates and Forecasts, By Condition (2021-2032) (USD Billion)
10.4.12.2 Rest of Asia Pacific Geriatric Medicine Market Estimates and Forecasts, By Therapeutics (2021-2032) (USD Billion)
10.4.12.3 Rest of Asia Pacific Geriatric Medicine Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.5 Middle East and Africa
10.5.1 Trends Analysis
10.5.2 Middle East and Africa Geriatric Medicine Market Estimates and Forecasts, by Country (2021-2032) (USD Billion)
10.5.3 Middle East and Africa Geriatric Medicine Market Estimates and Forecasts, By Condition (2021-2032) (USD Billion)
10.5.4 Middle East and Africa Geriatric Medicine Market Estimates and Forecasts, By Therapeutics (2021-2032) (USD Billion)
10.5.5 Middle East and Africa Geriatric Medicine Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.5.6 UAE
10.5.6.1 UAE Geriatric Medicine Market Estimates and Forecasts, By Condition (2021-2032) (USD Billion)
10.5.6.2 UAE Geriatric Medicine Market Estimates and Forecasts, By Therapeutics (2021-2032) (USD Billion)
10.5.6.3 UAE Geriatric Medicine Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.5.7 Saudi Arabia
10.5.7.1 Saudi Arabia Geriatric Medicine Market Estimates and Forecasts, By Condition (2021-2032) (USD Billion)
10.5.7.2 Saudi Arabia Geriatric Medicine Market Estimates and Forecasts, By Therapeutics (2021-2032) (USD Billion)
10.5.7.3 Saudi Arabia Geriatric Medicine Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.5.8 Qatar
10.5.8.1 Qatar Geriatric Medicine Market Estimates and Forecasts, By Condition (2021-2032) (USD Billion)
10.5.8.2 Qatar Geriatric Medicine Market Estimates and Forecasts, By Therapeutics (2021-2032) (USD Billion)
10.5.8.3 Qatar Geriatric Medicine Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.5.9 South Africa
10.5.9.1 South Africa Geriatric Medicine Market Estimates and Forecasts, By Condition (2021-2032) (USD Billion)
10.5.9.2 South Africa Geriatric Medicine Market Estimates and Forecasts By Therapeutics (2021-2032) (USD Billion)
10.5.9.3 South Africa Geriatric Medicine Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.5.10 Rest of Middle East & Africa
10.5.10.1 Rest of Middle East & Africa Geriatric Medicine Market Estimates and Forecasts, By Condition (2021-2032) (USD Billion)
10.5.10.2 Rest of Middle East & Africa Geriatric Medicine Market Estimates and Forecasts, By Therapeutics (2021-2032) (USD Billion)
10.5.10.3 Rest of Middle East & Africa Geriatric Medicine Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.6 Latin America
10.6.1 Trends Analysis
10.6.2 Latin America Geriatric Medicine Market Estimates and Forecasts, by Country (2021-2032) (USD Billion)
10.6.3 Latin America Geriatric Medicine Market Estimates and Forecasts, By Condition (2021-2032) (USD Billion)
10.6.4 Latin America Geriatric Medicine Market Estimates and Forecasts, By Therapeutics (2021-2032) (USD Billion)
10.6.5 Latin America Geriatric Medicine Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.6.6 Brazil
10.6.6.1 Brazil Geriatric Medicine Market Estimates and Forecasts, By Condition (2021-2032) (USD Billion)
10.6.6.2 Brazil Geriatric Medicine Market Estimates and Forecasts, By Therapeutics (2021-2032) (USD Billion)
10.6.6.3 Brazil Geriatric Medicine Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.6.7 Argentina
10.6.7.1 Argentina Geriatric Medicine Market Estimates and Forecasts, By Condition (2021-2032) (USD Billion)
10.6.7.2 Argentina Geriatric Medicine Market Estimates and Forecasts, By Therapeutics (2021-2032) (USD Billion)
10.6.7.3 Argentina Geriatric Medicine Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.6.8 Rest of Latin America
10.6.8.1 Rest of Latin America Geriatric Medicine Market Estimates and Forecasts, By Condition (2021-2032) (USD Billion)
10.6.8.2 Rest of Latin America Geriatric Medicine Market Estimates and Forecasts, By Therapeutics (2021-2032) (USD Billion)
10.6.8.3 Rest of Latin America Geriatric Medicine Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
11. Company Profiles
11.1 F. Hoffmann-La Roche Ltd.
11.1.1 Company Overview
11.1.2 Financial
11.1.3 Product/ Services Offered
11.1.4 SWOT Analysis
11.2 Takeda Pharmaceutical Company Ltd.
11.2.1 Company Overview
11.2.2 Financial
11.2.3 Product/ Services Offered
11.2.4 SWOT Analysis
11.3 Eli Lilly & Company
11.3.1 Company Overview
11.3.2 Financial
11.3.3 Product/ Services Offered
11.3.4 SWOT Analysis
11.4 AbbiVie, Inc
11.4.1 Company Overview
11.4.2 Financial
11.4.3 Product/ Services Offered
11.4.4 SWOT Analysis
11.5 Amgen, Inc
11.5.1 Company Overview
11.5.2 Financial
11.5.3 Product/ Services Offered
11.5.4 SWOT Analysis
11.6 Pfizer, Inc
11.6.1 Company Overview
11.6.2 Financial
11.6.3 Product/ Services Offered
11.6.4 SWOT Analysis
11.7 Novartis AG
11.7.1 Company Overview
11.7.2 Financial
11.7.3 Product/ Services Offered
11.7.4 SWOT Analysis
11.8 Abbott Laboratories Inc.
11.8.1 Company Overview
11.8.2 Financial
11.8.3 Product/ Services Offered
11.8.4 SWOT Analysis
11.9 Bristol-Myers Squibb Company
11.9.1 Company Overview
11.9.2 Financial
11.9.3 Product/ Services Offered
11.9.4 SWOT Analysis
11.10 UCB, Inc.
11.10.1 Company Overview
11.10.2 Financial
11.10.3 Product/ Services Offered
11.10.4 SWOT Analysis
12. Use Cases and Best Practices
13. Conclusion
An accurate research report requires proper strategizing as well as implementation. There are multiple factors involved in the completion of good and accurate research report and selecting the best methodology to compete the research is the toughest part. Since the research reports we provide play a crucial role in any company’s decision-making process, therefore we at SNS Insider always believe that we should choose the best method which gives us results closer to reality. This allows us to reach at a stage wherein we can provide our clients best and accurate investment to output ratio.
Each report that we prepare takes a timeframe of 350-400 business hours for production. Starting from the selection of titles through a couple of in-depth brain storming session to the final QC process before uploading our titles on our website we dedicate around 350 working hours. The titles are selected based on their current market cap and the foreseen CAGR and growth.
The 5 steps process:
Step 1: Secondary Research:
Secondary Research or Desk Research is as the name suggests is a research process wherein, we collect data through the readily available information. In this process we use various paid and unpaid databases which our team has access to and gather data through the same. This includes examining of listed companies’ annual reports, Journals, SEC filling etc. Apart from this our team has access to various associations across the globe across different industries. Lastly, we have exchange relationships with various university as well as individual libraries.
Step 2: Primary Research
When we talk about primary research, it is a type of study in which the researchers collect relevant data samples directly, rather than relying on previously collected data. This type of research is focused on gaining content specific facts that can be sued to solve specific problems. Since the collected data is fresh and first hand therefore it makes the study more accurate and genuine.
We at SNS Insider have divided Primary Research into 2 parts.
Part 1 wherein we interview the KOLs of major players as well as the upcoming ones across various geographic regions. This allows us to have their view over the market scenario and acts as an important tool to come closer to the accurate market numbers. As many as 45 paid and unpaid primary interviews are taken from both the demand and supply side of the industry to make sure we land at an accurate judgement and analysis of the market.
This step involves the triangulation of data wherein our team analyses the interview transcripts, online survey responses and observation of on filed participants. The below mentioned chart should give a better understanding of the part 1 of the primary interview.
Part 2: In this part of primary research the data collected via secondary research and the part 1 of the primary research is validated with the interviews from individual consultants and subject matter experts.
Consultants are those set of people who have at least 12 years of experience and expertise within the industry whereas Subject Matter Experts are those with at least 15 years of experience behind their back within the same space. The data with the help of two main processes i.e., FGDs (Focused Group Discussions) and IDs (Individual Discussions). This gives us a 3rd party nonbiased primary view of the market scenario making it a more dependable one while collation of the data pointers.
Step 3: Data Bank Validation
Once all the information is collected via primary and secondary sources, we run that information for data validation. At our intelligence centre our research heads track a lot of information related to the market which includes the quarterly reports, the daily stock prices, and other relevant information. Our data bank server gets updated every fortnight and that is how the information which we collected using our primary and secondary information is revalidated in real time.
Step 4: QA/QC Process
After all the data collection and validation our team does a final level of quality check and quality assurance to get rid of any unwanted or undesired mistakes. This might include but not limited to getting rid of the any typos, duplication of numbers or missing of any important information. The people involved in this process include technical content writers, research heads and graphics people. Once this process is completed the title gets uploader on our platform for our clients to read it.
Step 5: Final QC/QA Process:
This is the last process and comes when the client has ordered the study. In this process a final QA/QC is done before the study is emailed to the client. Since we believe in giving our clients a good experience of our research studies, therefore, to make sure that we do not lack at our end in any way humanly possible we do a final round of quality check and then dispatch the study to the client.
Key Segments:
By Condition
Cardiovascular Diseases
Cancer
Arthritis & Bone Health
Respiratory Diseases
Neurological Disorders
Diabetes and Metabolic Disorders
Others
By Therapeutics
Analgesics
Antihypertensive
Proton Pump Inhibitors
Statins
Antidiabetic
Anticoagulant
Antipsychotic
Others
By Distribution Channel
Hospital Pharmacy
Online Pharmacy
Retail Pharmacy
Request for Segment Customization as per your Business Requirement: Segment Customization Request
Regional Coverage:
North America
US
Canada
Mexico
Europe
Germany
France
UK
Italy
Spain
Poland
Turkey
Rest of Europe
Asia Pacific
China
India
Japan
South Korea
Singapore
Australia
Rest of Asia Pacific
Middle East & Africa
UAE
Saudi Arabia
Qatar
South Africa
Rest of Middle East & Africa
Latin America
Brazil
Argentina
Rest of Latin America
Request for Country Level Research Report: Country Level Customization Request
Available Customization
With the given market data, SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report:
Detailed Volume Analysis
Criss-Cross segment analysis (e.g. Product X Application)
Competitive Product Benchmarking
Geographic Analysis
Additional countries in any of the regions
Customized Data Representation
Detailed analysis and profiling of additional market players
The Healthcare Logistics Market was valued at USD 88.04 billion in 2023 and is expected to reach USD 192.81 billion by 2032, growing at a CAGR of 9.07%.
The Vitrification Market Size, valued at USD 8.23 billion in 2023, is projected to reach USD 33.04 billion by 2032, growing at a CAGR of 16.75%.
The Peptide Microarray Market size was estimated at USD 830.83 million in 2023 and is expected to reach USD 1245.37 million by 2032 with a growing CAGR of 4.6% during the forecast period of 2024-2032.
The AI in Healthcare Market Size was valued at USD 22.5 Billion in 2023 and will reach USD 370.14 Billion by 2032 & grow at a CAGR of 36.5% by 2024-2032.
Topical drugs market size was valued at USD 195.77 billion in 2024 and is expected to reach USD 311.88 billion by 2032, growing at a CAGR of 6.02% over the forecast period of 2025-2032.
The Robotic Surgical Procedures Market to grow from USD 10.66 billion in 2023 to USD 51.91 billion by 2032, at a 19.27% CAGR.
Hi! Click one of our member below to chat on Phone
© 2025 All Rights Reserved by SNS Insider Pvt Ltd
